newsfilter
← Latest News
GlobeNewswire·

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Systemic Lupus Erythematosus

Phase 1 trial initiation expected before yearend with topline results in 1H 2022 BLACKSBURG, Va., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ:LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced